ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference (MBCC) IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine Read More
Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care
Agendia is disappointed with the recent update to the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines and with the decision to move forward without key research that we feel would have a material Read More
Agendia and Partners Receive $6.8 million from European Commission to Study Targeted Therapies for Colorectal Cancer
IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and several European partners have received a $6.8 million European Commission grant to study targeted therapies for colorectal cancer (CRC). The grantees will test therapies matched Read More
Agendia’s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium
Satellite Symposium and Dinner Presentation Will Offer Latest Insights on Genomic Testing and Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research highlighting the value of Agendia’s MammaPrint® and BluePrint® genomic tests Read More